1. Home
  2. SPHL vs NXL Comparison

SPHL vs NXL Comparison

Compare SPHL & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$2.30

Market Cap

7.1M

ML Signal

N/A

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

N/A

Current Price

$1.41

Market Cap

7.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPHL
NXL
Founded
2002
2010
Country
Singapore
United States
Employees
N/A
N/A
Industry
Homebuilding
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
7.5M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
SPHL
NXL
Price
$2.30
$1.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 2.2M
35.6K
Earning Date
09-23-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.76
EPS
★ N/A
N/A
Revenue
N/A
★ $301,647.00
Revenue This Year
N/A
$14.37
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 78.78
52 Week Low
$0.36
$0.22
52 Week High
$25.11
$80.40

Technical Indicators

Market Signals
Indicator
SPHL
NXL
Relative Strength Index (RSI) 45.78 27.94
Support Level N/A $0.22
Resistance Level $2.98 $5.36
Average True Range (ATR) 0.50 0.19
MACD -0.03 0.13
Stochastic Oscillator 0.27 7.42

Price Performance

Historical Comparison
SPHL
NXL

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Share on Social Networks: